100 related articles for article (PubMed ID: 25823606)
21. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
22. The effect of maternal age, parity, and fetal sex on the amniotic fluid and maternal serum levels of CA 125, CA 19.9, CA 15.3, and CEA.
Tayyar M; Tutus A
Int J Fertil Womens Med; 1999; 44(5):256-9. PubMed ID: 10569455
[TBL] [Abstract][Full Text] [Related]
23. Effect of the coronavirus pandemic on tumor markers.
Purut YE; Giray B; Gurbuz E
J Med Virol; 2021 Sep; 93(9):5405-5408. PubMed ID: 33932304
[TBL] [Abstract][Full Text] [Related]
24. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
25. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study.
Poncelet C; Fauvet R; Yazbeck C; Coutant C; Darai E
Eur J Surg Oncol; 2010 Nov; 36(11):1066-72. PubMed ID: 20817462
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
[TBL] [Abstract][Full Text] [Related]
27. Effect of obesity-related plasma hemodilution on serum tumor marker concentration in women.
Park M; Chang IH; Kang H; Han SS
J Obstet Gynaecol Res; 2015 May; 41(5):784-9. PubMed ID: 25421332
[TBL] [Abstract][Full Text] [Related]
28. Measurement of four tumor marker antigens in the sera of pregnant women.
Cheli CD; Morris DL; Neaman IE; Dai J; Allard WJ; Yeung KK
J Clin Lab Anal; 1999; 13(1):35-9. PubMed ID: 10025736
[TBL] [Abstract][Full Text] [Related]
29. Conventional Tumor Markers in Cerebralspinal Fluid in Patients with Elevated Serum Tumor Markers and without Central Nervous System Malignant Diseases.
Liu ZJ; Shi Q; Lu B; Zhang Z; Tian CL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Oct; 38(5):539-542. PubMed ID: 27825410
[TBL] [Abstract][Full Text] [Related]
30. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
31. Maternal serum Ca125 and Ca15-3 antigen levels in normal and pathological pregnancy.
Bon GG; Kenemans P; Verstraeten AA; Go S; Philipi PA; van Kamp GJ; van Geijn HP; van Vugt JM
Fetal Diagn Ther; 2001; 16(3):166-72. PubMed ID: 11316933
[TBL] [Abstract][Full Text] [Related]
32. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
Gedik GK; Kiratli PO; Tascioglu B; Aras T
Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
[TBL] [Abstract][Full Text] [Related]
33. The concentrations of bile acids and erythropoietin in pregnant women with intrahepatic cholestasis and the state of the fetus and newborn.
Kowalska-Kańka A; Maciejewski T; Niemiec KT
Med Wieku Rozwoj; 2013; 17(3):232-45. PubMed ID: 24296447
[TBL] [Abstract][Full Text] [Related]
34. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
Ng WW; Tong KJ; Tam TN; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
[TBL] [Abstract][Full Text] [Related]
35. The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type.
Agrawal AK; Jelen M; Rudnicki J; Grzebieniak Z; Zyśko D; Kielan W; Słonina J; Marek G
Folia Histochem Cytobiol; 2010 Jan; 48(1):26-9. PubMed ID: 20529812
[TBL] [Abstract][Full Text] [Related]
36. [Cryptates applied in tumor marker assays (CEA, AFP, CA 15.3, CA19.9): evaluation of Kryptor (Cis-Bio) analyser].
Gherardi C; Roumier AS; Dubucquoi S; Dessaint JP
Ann Biol Clin (Paris); 1998; 56(1):92-5. PubMed ID: 9754229
[No Abstract] [Full Text] [Related]
37. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H;
Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526
[TBL] [Abstract][Full Text] [Related]
38. Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients.
Shu J; Li CG; Liu YC; Yan XC; Xu X; Huang XE; Cao J; Li Y; Lu YY; Wu XY; Liu J; Xiang J
Asian Pac J Cancer Prev; 2012; 13(5):2399-403. PubMed ID: 22901228
[TBL] [Abstract][Full Text] [Related]
39. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of tumour markers in molar pregnancy.
Hegab HM; Schindler AE; Rizk M; Ramadan M
Arch Gynecol Obstet; 2003 Aug; 268(3):151-4. PubMed ID: 12942241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
